These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 21886507)
1. Genomic testing and therapies for breast cancer in clinical practice. Haas JS; Phillips KA; Liang SY; Hassett MJ; Keohane C; Elkin EB; Armstrong J; Toscano M J Oncol Pract; 2011 May; 7(3 Suppl):e1s-7s. PubMed ID: 21886507 [TBL] [Abstract][Full Text] [Related]
2. Genomic testing and therapies for breast cancer in clinical practice. Haas JS; Phillips KA; Liang SY; Hassett MJ; Keohane C; Elkin EB; Armstrong J; Toscano M Am J Manag Care; 2011 May; 17(5 Spec No):e174-81. PubMed ID: 21711068 [TBL] [Abstract][Full Text] [Related]
3. Gene expression profile testing for breast cancer and the use of chemotherapy, serious adverse effects, and costs of care. Haas JS; Liang SY; Hassett MJ; Shiboski S; Elkin EB; Phillips KA Breast Cancer Res Treat; 2011 Nov; 130(2):619-26. PubMed ID: 21681446 [TBL] [Abstract][Full Text] [Related]
4. Tradeoffs of using administrative claims and medical records to identify the use of personalized medicine for patients with breast cancer. Liang SY; Phillips KA; Wang G; Keohane C; Armstrong J; Morris WM; Haas JS Med Care; 2011 Jun; 49(6):e1-8. PubMed ID: 21422962 [TBL] [Abstract][Full Text] [Related]
5. The impact of gene expression profile testing on confidence in chemotherapy decisions and prognostic expectations. Panattoni L; Lieu TA; Jayasekera J; O'Neill S; Mandelblatt JS; Etzioni R; Phelps CE; Ramsey SD Breast Cancer Res Treat; 2019 Jan; 173(2):417-427. PubMed ID: 30306429 [TBL] [Abstract][Full Text] [Related]
6. Population-based study of the effect of gene expression profiling on adjuvant chemotherapy use in breast cancer patients under the age of 65 years. Potosky AL; O'Neill SC; Isaacs C; Tsai HT; Chao C; Liu C; Ekezue BF; Selvam N; Kessler LG; Zhou Y; Schwartz MD Cancer; 2015 Nov; 121(22):4062-70. PubMed ID: 26291519 [TBL] [Abstract][Full Text] [Related]
7. Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis. Medical Advisory Secretariat Ont Health Technol Assess Ser; 2010; 10(23):1-57. PubMed ID: 23074401 [TBL] [Abstract][Full Text] [Related]
8. Hospital Rurality and Gene Expression Profiling for Early-Stage Breast Cancer among Iowa Residents (2010-2018). Riley D; Charlton M; Chrischilles EA; Lizarraga IM; Phadke S; Smith BJ; Skibbe A; Lynch CF Breast J; 2022; 2022():8582894. PubMed ID: 36111211 [TBL] [Abstract][Full Text] [Related]
9. Disparities in Use of Human Epidermal Growth Hormone Receptor 2-Targeted Therapy for Early-Stage Breast Cancer. Reeder-Hayes K; Peacock Hinton S; Meng K; Carey LA; Dusetzina SB J Clin Oncol; 2016 Jun; 34(17):2003-9. PubMed ID: 27069085 [TBL] [Abstract][Full Text] [Related]
10. Underutilization of gene expression profiling for early-stage breast cancer in California. Cress RD; Chen YS; Morris CR; Chew H; Kizer KW Cancer Causes Control; 2016 Jun; 27(6):721-7. PubMed ID: 27097910 [TBL] [Abstract][Full Text] [Related]
11. Trastuzumab-containing regimens for metastatic breast cancer. Balduzzi S; Mantarro S; Guarneri V; Tagliabue L; Pistotti V; Moja L; D'Amico R Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD006242. PubMed ID: 24919460 [TBL] [Abstract][Full Text] [Related]
12. Treatment of early-stage human epidermal growth factor 2-positive cancers among medicare enrollees: age and race strongly associated with non-use of trastuzumab. Vaz-Luis I; Lin NU; Keating NL; Barry WT; Lii J; Burstein HJ; Winer EP; Freedman RA Breast Cancer Res Treat; 2016 Aug; 159(1):151-62. PubMed ID: 27484879 [TBL] [Abstract][Full Text] [Related]
13. Utilization of HER2 genetic testing in a multi-institutional observational study. Goddard KA; Bowles EJ; Feigelson HS; Habel LA; Alford SH; McCarty CA; Nekhlyudov L; Onitilo AA; Rahm AK; Webster JA Am J Manag Care; 2012 Nov; 18(11):704-12. PubMed ID: 23198713 [TBL] [Abstract][Full Text] [Related]
14. HER2 evaluation and its impact on breast cancer treatment decisions. Goddard KA; Weinmann S; Richert-Boe K; Chen C; Bulkley J; Wax C Public Health Genomics; 2012; 15(1):1-10. PubMed ID: 21540562 [TBL] [Abstract][Full Text] [Related]
15. Impact of Pertuzumab and Ado-Trastuzumab Emtansine on Cumulative Avoidance of Recurrence Among Women Treated for Locally Advanced, Inflammatory, or Early-Stage Nonmetastatic HER2-Positive Breast Cancer in the United States. Sussell JA; Press DJ; Hansen SA; Kim E; Du Toit Y; Fung A Adv Ther; 2023 Sep; 40(9):3857-3874. PubMed ID: 37358705 [TBL] [Abstract][Full Text] [Related]
16. Efficacy of adjuvant trastuzumab in women with HER2-positive T1a or bN0M0 breast cancer: a population-based cohort study. Ali S; Hendry J; Le D; Mondal PK; Sami A; Chalchal H; Haider K; Ahmed O; El-Gayed A; Wright P; Pauls M; Johnson K; Ahmed S Sci Rep; 2022 Jan; 12(1):1068. PubMed ID: 35058536 [TBL] [Abstract][Full Text] [Related]
17. Impact of gene-expression profiling in patients with early breast cancer when applied outside the guideline directed indication area. Schreuder K; Kuijer A; Rutgers EJT; Smorenburg CH; van Dalen T; Siesling S Eur J Cancer; 2017 Oct; 84():270-277. PubMed ID: 28844015 [TBL] [Abstract][Full Text] [Related]
18. Gene expression profiling and expanded immunohistochemistry tests to guide the use of adjuvant chemotherapy in breast cancer management: a systematic review and cost-effectiveness analysis. Ward S; Scope A; Rafia R; Pandor A; Harnan S; Evans P; Wyld L Health Technol Assess; 2013 Oct; 17(44):1-302. PubMed ID: 24088296 [TBL] [Abstract][Full Text] [Related]
19. Clinical practice patterns and cost effectiveness of human epidermal growth receptor 2 testing strategies in breast cancer patients. Phillips KA; Marshall DA; Haas JS; Elkin EB; Liang SY; Hassett MJ; Ferrusi I; Brock JE; Van Bebber SL Cancer; 2009 Nov; 115(22):5166-74. PubMed ID: 19753618 [TBL] [Abstract][Full Text] [Related]